References
1. Fukuhara E. Mine T., Kishima H, Kitagaki R, Ishihara M. Increase in Heart Rate-dependent Left Atrial Pressure is Associated with Symptoms in Patients with Paroxysmal Atrial Fibrillation. J. Cardiovasc Electrophysiol 2022 (In press)
2. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, Gupta D. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014; 16:965-72.
3. Mitter SS, Shah SJ, Thomas JD. A test in context: E/A and E/e′ to assess diastolic dysfunction and LV filling pressure. J Am Coll of Cardiol. 2017; 69: 1451-64.
4. Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF, Van Gelder IC, Ellinor PT, Benjamin EJ. Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities. Circulation. 2012; 125:2933-2943.
5. van den Berg MP, Hassink RJ, Tuinenburg AE, van Sonderen EF, Lefrandt JD, de Kam PJ, van Gelder IC, Smit AJ, Sanderman R, Crijns HJ. Quality of life in patients with paroxysmal atrial fibrillation and its predictors: importance of the autonomic nervous system. Eur Heart J. 2001; 22:247-253.
8. Rho RW, Page RL. Asymptomatic atrial fibrillation. Progress in cardiovascular diseases. 2005; 48:79-87.
9. Rienstra M, Vermond RA, Crijns HJ, Tijssen JG, Van Gelder IC, RACE Investigators. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. Heart Rhythm. 2014; 11:939-945.
10. Gibbs H, Freedman B, Rosenqvist M, Virdone S, Al Mahmeed W, Ambrosio G, Camm AJ, Jacobson B, Jerjes-Sanchez C, Kayani G, Oto A. Clinical outcomes in asymptomatic and symptomatic atrial fibrillation presentations in GARFIELD-AF: implications for AF screening. The American Journal of Medicine. 2021; 134:893-901.
11. Bano A, Rodondi N, Beer JH, Moschovitis G, Kobza R, Aeschbacher S, Baretella O, Muka T, Stettler C, Franco OH, Conte G. Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss‐AF Study. J Am Heart Assoc 2021; 10: e021800.
12. Noseworthy, P.A., Kaufman, E.S., Chen, L.Y., Chung, M.K., Elkind, M.S., Joglar, J.A., Leal, M.A., McCabe, P.J., Pokorney, S.D., Yao. Subclinical and device-detected atrial fibrillation: pondering the knowledge gap: a scientific statement from the American Heart Association. Circulation 2019; 140: e944-e963.
13. Quer G, Freedman B, Steinhubl SR. Screening for atrial fibrillation: predicted sensitivity of short, intermittent electrocardiogram recordings in an asymptomatic at-risk population. Europace. 2020; 22:1781-1787.
14. Kashou AH, Adedinsewo DA, Noseworthy PA. Subclinical Atrial Fibrillation: A Silent Threat with Uncertain Implications. Annu Rev Med 2022; 73: 355-362.
15. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. 2017; 14: e275-e433
16. ClinicaltTrials.gov Identifier: NCT01938248. The Apixaban for the Reduction of Thrombo-Embolism in Patients with Device-Detected Sub-Clinical Atrial Fibrillation (ARTESIA) trial
17. ClinicaltTrials.gov Identifier: NCT02618577. Non-vitamin K Antagonist Oral Anticoagulants with Atrial High-Rate Episodes (NOAH).
18. Ding WY, Mandrola J, Gupta D. Left atrial appendage occlusion: past, present and future. Thrombosis and Haemostasis. 2020; 120:1484-1491.